研究人员开发ACBI3,一种KRAS突变定向药物,为17%至25%的癌症提供更好的治疗。 Researchers develop ACBI3, a KRAS mutation-targeting drug, offering improved treatment for 17-25% of cancers.

邓迪大学和博林格尔·伊安赫尔海姆大学的研究人员研制了ACBI3,一种针对KRAS突变的药物,这种药物在17-25%的癌症中出现。 Researchers at the University of Dundee and Boehringer Ingelheim have developed ACBI3, a drug that targets KRAS mutations, which occur in 17-25% of cancers. ACBI3,即PROTAC,可以消除17个常见的KRAS变种人中的13个,提供比目前方案更有效的治疗方法。 ACBI3, a PROTAC, can eliminate 13 of the 17 common KRAS mutants, offering a more effective treatment approach than current options. 该化合物将通过博林格格海姆的opnMe门户免费提供,以促进对这一关键癌症点的进一步研究. The compound will be available for free through Boehringer Ingelheim's opnMe portal to facilitate further research on this critical cancer target.